ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

3.88USD-0.04 (-1.02%)Market Closed

Market Summary

USD3.88-0.04

Market Closed

-1.02%

ABUS Stock Price

View Fullscreen

ABUS RSI Chart

ABUS Valuation

Market Cap

732.2M

Price/Earnings (Trailing)

-9.84

Price/Sales (Trailing)

56.39

EV/EBITDA

-6.67

Price/Free Cashflow

-9.28

ABUS Price/Sales (Trailing)

ABUS Profitability

EBT Margin

-547.54%

Return on Equity

-64.89%

Return on Assets

-49.49%

Free Cashflow Yield

-10.78%

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

13.0M

Rev. Growth (Yr)

-77.09%

Rev. Growth (Qtr)

-28.58%

ABUS Earnings

Earnings (TTM)

-74.4M

Earnings Growth (Yr)

-9.4%

Earnings Growth (Qtr)

7.44%

Breaking Down ABUS Revenue

Last 7 days

6.0%

Last 30 days

28.2%

Last 90 days

43.2%

Trailing 12 Months

81.9%

How does ABUS drawdown profile look like?

ABUS Financial Health

Current Ratio

6.69

ABUS Investor Care

Shares Dilution (1Y)

13.59%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.0M	0	0	0
2023	33.1M	23.5M	22.2M	18.1M
2022	21.5M	33.4M	36.0M	39.0M
2021	7.5M	8.4M	10.2M	11.0M
2020	6.2M	6.5M	6.7M	6.9M
2019	5.2M	4.6M	9.5M	6.0M
2018	11.9M	12.1M	6.8M	5.9M
2017	3.8M	6.1M	8.4M	10.7M
2016	19.0M	13.2M	7.3M	1.5M
2015	15.2M	16.8M	16.5M	24.9M
2014	17.8M	16.7M	18.1M	15.0M
2013	17.9M	17.1M	16.3M	15.5M
2012	17.1M	17.5M	17.9M	18.3M
2011	20.2M	19.0M	17.8M	16.6M
2010	0	0	0	21.4M
2009	0	0	0	14.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

CEO	Mr. William H. Collier
WEBSITE	arbutusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	96

Arbutus Biopharma Corp Frequently Asked Questions

What is the ticker symbol for Arbutus Biopharma Corp? What does ABUS stand for in stocks?

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arbutus Biopharma Corp (ABUS)?

As of Thu Jul 25 2024, market cap of Arbutus Biopharma Corp is 739.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers.

Is Arbutus Biopharma Corp a good stock to buy?

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

What is Arbutus Biopharma Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ABUS's PE ratio (Price to Earnings) is -9.95 and Price to Sales (PS) ratio is 56.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.